CA
NZ
UK
AU
IND
US
Addex is a Geneva-based, clinical-stage biopharmaceutical company developing small molecule allosteric modulators for neurological disorders. Its lead candidate, dipraglurant, is being evaluated for future development in brain injury recovery, and it has GABAB programs aimed at substance use disorders and chronic cough.
Alvotech is a biotechnology company that develops and manufactures biosimilar medicines, with an integrated operation in Reykjavik, Iceland. It has five approvedBiosimilarsmarketed across multiple global markets, sold largely through commercial partners.
Aveanna is an Atlanta-based home care provider operating in 39 states, serving medically complex, high-cost patients with services such as nursing, hospice, rehabilitation, school-based nursing and enteral nutrition delivery. Its largest segment, private duty services, generated $574.2 million of third quarter revenue.
Beyond Air is a Garden City, New York-based commercial-stage medical device and biopharmaceutical company developing nitric oxide therapies. Its only commercial product, LungFit PH, is a cylinder-free system approved by the FDA for term and near-term neonates with hypoxic respiratory failure.
Fennec is a specialty pharmaceutical company based in Research Triangle Park, North Carolina. The company describes PEDMARK as the first and only FDA-approved therapy to reduce the risk of cisplatin-related hearing loss in pediatric patients with localized, non-metastatic solid tumors. A European version is …
PepGen is a Boston-based, clinical-stage biotechnology company founded in 2018. Its Enhanced Delivery Oligonucleotide technology uses cell-penetrating peptides to improve the uptake of conjugated oligonucleotide therapies. Its lead candidate, PGN-EDODM1, is being studied in myotonic dystrophy type 1 in the Phase 2 FREEDOM2-DM1 trial.
SeaStar is a Denver-based, commercial-stage medical device company developing extracorporeal therapies built on its Selective Cytopheretic Device platform, which aims to neutralize overactive immune cells in critically ill patients. Its first commercial product received FDA approval in 2024 for pediatric use.
Veradermics is a dermatologist-founded, late-stage biopharmaceutical company based in New Haven, Connecticut. Its lead candidate, VDPHL01, is an oral, non-hormonal extended-release minoxidil tablet in Phase 3 development for pattern hair loss in men and women.
Vivani is an Alameda, California-based, clinical-stage biopharmaceutical company developing miniature, ultra-long-acting drug implants using its NanoPortal technology. Its lead program, NPM-139, is a semaglutide implant designed to deliver six to twelve months of continuous dosing for chronic weight management.
● Full-year non-GAAP EPS guidance raised to $12.80 to $13.00
Please wait processing your request...